comparemela.com

Latest Breaking News On - Department of oncology at lausanne university - Page 1 : comparemela.com

BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.

United kingdomUnited statesJan lillebyGraham morrellTony mokEnriqueta felipMartin olinSolange petersJohn heymachInvestor relations international mediaHebron university hospitalMd anderson cancer centerChinese university of hong kongDepartment of oncology at lausanne universityDepartment of clinical oncologyClinical development

BerGenBio ASA: BerGenBio Reports Fourth Quarter 2022 Financial Results and Provides Business Update

BERGEN, Norway, Feb. 16, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet medical

United kingdomUnited statesDennis riedlJan lillebyMartin olinJohn heymachTony mokGraham morrellEnriqueta felipPrnewswire bergenbioSolange petersInvestor relations international mediaHebron university hospitalMd anderson cancer centerChinese university of hong kongDepartment of oncology at lausanne university

BerGenBio ASA: BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

- Distinguished global experts appointed to strengthen bemcentinib development in STK11m NSCLC - BERGEN, Norway, Feb. 2, 2023 /PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage

United statesUnited kingdomComunidad autonoma de catalunaJan lillebyMartin olinSchwierige zeitenJohn heymachGraham morrellTony mokCristina olivaEnriqueta felipPrnewswire bergenbioSolange petersUniversity of albertaNational cancer instituteAmerican society of clinical oncology

BerGenBio Announces the Establishment of Oncology Scientific Advisory Board

/PRNewswire/ BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for severe unmet.

United statesUnited kingdomComunidad autonoma de catalunaJan lillebyMartin olinJohn heymachTony mokGraham morrellCristina olivaEnriqueta felipPrnewswire bergenbioSolange petersUniversity of albertaNational cancer instituteAmerican society of clinical oncologyMd anderson cancer center

vimarsana © 2020. All Rights Reserved.